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The cholesterol-lowering efficacy of plant stanol ester (STAEST) added to fat- ormilk-based products is well documented. However,
their efficacy when added to nondairy liquid drinks is less certain.Therefore, we have investigated the cholesterol-lowering efficacy
of STAEST added to a soymilk-based minidrink in the hypercholesterolemic subjects. In a randomized, double-blind, placebo-
controlled parallel study, the intervention group (𝑛 = 27) consumed 2.7 g/d of plant stanols as the ester in soymilk-basedminidrink
(65mL/d) with the control group (𝑛 = 29) receiving the same drink without added plant stanols once a day with a meal for 4 weeks.
Serum total, LDL, and non-HDL cholesterol concentrations were reduced by 8.0, 11.1, and 10.2% compared with controls (𝑃 < 0.05
for all). Serum plant sterol concentrations and their ratios to cholesterol declined by 12–25% from baseline in the STAEST group
while the ratio of campesterol to cholesterol was increased by 10% in the controls (𝑃 < 0.05 for all). Serum precursors of cholesterol
remained unchanged in both groups. In conclusion, STAEST-containing soymilk-based low-fat minidrink consumed once a day
with a meal lowered LDL and non-HDL cholesterol concentrations without evoking any side effects in subjects consuming normal
Western diet. The clinical trial registration number is NCT01716390.
1. Introduction
It is known that the best way to reduce the risk of coronary
artery disease (CAD) is to lower the low-density lipoprotein
(LDL) cholesterol level. It has been estimated that each 1%
reduction in LDL cholesterol achieves a 1% reduction in the
risk of CAD [1]. Phytosterols have attracted considerable
interest as cholesterol-lowering agents since the 1950s [2] due
to their ability to reduce the serum LDL cholesterol level by
interfering with cholesterol absorption. In a recent meta-
analysis, LDL cholesterol values were reduced by 9% with a
2 g daily dose of plant stanols, and furthermore increasing the
daily intake of plant stanols was found to dose-dependently
reduce LDL cholesterol [3]. Most of the studies included
in the plant stanol ester (STAEST) meta-analysis have been
performed with solid food format, and only in four studies
out of 61 has the plant stanol been in liquid dairy and one in
a nondairy form [3].
TheEFSANDAPanel concluded in its heath claimdossier
that STAEST at a daily intake of 3 g plant stanols (range of
2.7 g to 3.3 g) in matrices approved by Regulation (EC) No
376/2010 (yellow fat spreads, dairy products,mayonnaise, and
salad dressings) can lower LDL cholesterol by 11.4% (95% CI:
9.8–13.0) and STAEST added to foods such as margarine-
type spreads,mayonnaise, salad dressings, and dairy products
such asmilk, yoghurts including low-fat yoghurts, and cheese
has been shown consistently to lower blood LDL cholesterol
levels, but the extent of the cholesterol-lowering effect of
plant sterols/stanols added to other food formats is less well
established [4]. From a theoretical point of view one could
speculate that there might be no difference in the cholesterol-
lowering effect of plant stanols or plant sterols based dairy
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versus nondairy products, but nonetheless the impact of the
different food formats and background diets needs to be
confirmed experimentally.
To this end, the aim of this investigation was to evaluate
the efficacy of plant stanols (2.7 g/d) consumed once a day
as a low-fat STAEST soymilk-based minidrink to lower LDL
cholesterol level as well as its safety in a placebo-controlled,
randomized, parallel study in individuals with mild to mod-
erate hypercholesterolemia.
2. Subjects and Methods
2.1. Subjects. The subjects were recruited by advertisements
placed in local papers in Uppsala, Sweden, from the pool
of volunteers at Foodfiles (former Good Food Practice),
Uppsala, Sweden, and via webpages. Inclusion criteria were
as follows: age 25–65 years, serum total cholesterol level 5.2–
8.5mmol/L, and normal liver, kidney, and thyroid function.
Exclusion criteria were as follows: severe obesity (BMI >
35.0 kg/m2), consumption of lipid lowering medication or
other drugs affecting lipid metabolism, consumption of plant
stanol or plant sterol products, history of unstable CAD,
myocardial infarction or unstable angina pectoris within the
previous 6 months, transient ischemic attack or stroke within
1 year, diabetes, malignant disease, being pregnant or lac-
tating, alcohol or substance abuse, or lack of suitability for
participation in the trial. On the basis of these criteria, 90
subjects were screened, and of these 61 subjects were ulti-
mately included in the intervention. Two subjects withdrew
from the control group due to an adverse event and three
subjects from the STAEST group due to an adverse event,
unwillingness to continue or a major protocol violation (8 kg
weight reduction). Thus, a total of 56 subjects completed the
study.
Five subjects had hypertension, for which two subjects
were taking diuretics and four were receiving angiotensin
converting enzyme or angiotensin receptor blocking agents.
One subject was using hormone replacement therapy. The
subjects were requested to keep their medication, weight,
lifestyle, and dietary habits unchanged during the study.
All subjects gave their written informed consent for the
intervention. The intervention was performed according to
the principles of the Declaration of Helsinki. The study pro-
tocol was approved by the Ethical Regional Review Board in
Uppsala, Sweden.
2.2. Study Design. The intervention was a randomized, dou-
ble-blind, placebo-controlled trial with parallel design. It
contained a 2-week screening phase and a 4-week interven-
tion. During the 2-week screening phase, the subjects were
screened for inclusion and exclusion criteria. After screening,
the subjects were randomized according to a randomization
treatment list generated by an independent statistician. The
STAEST group (𝑛 = 27) consumed a soy-based minidrink
with added plant stanol esters and the control group (𝑛 = 29)
the same minidrink without added plant stanols daily for 4
weeks with either lunch or dinner. The baseline characteris-
tics of the subjects are shown in Table 1.
Samples for routine laboratory measurements were taken
to ensure normal health status before the entry and at the
end of the intervention. In addition, diseases, possible med-
ications, and use of vitamins or other nutrient supplements
were recorded at all visits and possible adverse events at visits
of weeks 3 and 4. Samples for laboratory measurements were
taken at the beginning (weeks −1 and 0) and at the end of
the intervention (weeks 3 and 4) for lipids and on weeks 0
and 4 to analyze serum concentrations of serum squalene
and noncholesterol sterols. For the lipids, the mean values
of weeks −1 and 0 and weeks 3 and 4 were used for in the
statistical analyses.
2.3. Diet. The soy-based minidrinks were provided by Raisio
Nutrition Ltd. (Raisio, Finland). The test minidrinks (65mL)
contained energy 151 kJ (36 kcal), protein 1.1 g, carbohydrates
2.1 g, absorbable fats 2.5 g, and fiber 0.5 g. The subjects were
advised to continue with their habitual diet and take the
test minidrink (65mL/d) directly after lunch or dinner. The
analyzed daily amount of plant stanols was 2.8 g (27.9%
campestanol and 72.1% sitostanol) in the STAEST minidrink
which amounted to 2.7 g taking into account the compliance
reported by the subjects. To verify the compliance, the
subjects were asked to fill in a formdetailing the use of the test
minidrinks including timing (date, precise clock time, lunch,
or dinner) in a study diary on every day for the 4 weeks of
the trial.They were also asked to fill in any failures to take the
product and also if they did not consume the total contents
of the test mini-drink.
The diet was monitored from a 3-d (2 weekdays and 1
weekend day) food diary kept at baseline and at the end of the
intervention.Thenutrients in the food diaries were calculated
by using Dietist XP (version 3, Bromma, Sweden).
2.4. Clinical and LaboratoryMeasurements. Body weight was
measured with a digital scale and height using a stadiometer.
All blood samples were collected after 12 h overnight fast.
Laboratory samples were analyzed with routine standardized
methods at the Aleris Medilab, Ta¨by, Sweden.
Serum total andHDL cholesterol and serum triglycerides
were analyzed with an Architect c16000 Clinical Chemistry
Analyzer (Abbott Diagnostics Division, USA) using enzy-
matic methods (Abbott Scandinavia AB, Solna, Sverige).
The LDL cholesterol level was calculated by the Friedewald
equation.
Serum cholesterol, cholesterol precursors (squalene, cho-
lestenol, desmosterol, and lathosterol), plant sterols (sitos-
terol, campesterol, and avenasterol), plant stanol (sitostanol),
and cholestanol were quantified from nonsaponifiable serum
material by capillary gas-liquid chromatography (GLC) (Agi-
lent 6890N Network GC System, Agilent Technologies,
Wilmington, DE, USA) equipped with a 50m long Ultra 2
capillary column (5% phenyl-methyl siloxane) (Agilent Tech-
nologies, Wilmington, DE, USA) [5]. Serum measurements
were expressed as concentrations (𝜇g/dL), but also in terms of
102 × mmol/mol of cholesterol (called the ratio in the text)
by dividing the concentrations with the cholesterol value
of the same GLC run in order to eliminate the impact of
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Table 1: Clinical variables during the study.
Control group (𝑛 = 29) STAEST group (𝑛 = 27)
𝑃
a
Baseline Intervention Baseline Intervention
N (M/W) 7/22 4/23 0.506b
Age (y) 54.2 ± 1.8 55.3 ± 1.6 0.837b
Weight (kg) 70.1 ± 1.8 70.0 ± 1.8 66.3 ± 1.8 66.0 ± 1.8 0.696
BMI (kg/m2) 24.5 ± 0.5 24.5 ± 0.5 23.7 ± 0.5 23.6 ± 0.5 0.696
Blood leukocytes (109/L)c 5.10 ± 0.26 4.64 ± 0.25 5.26 ± 0.20 4.99 ± 0.21 0.681
Blood erythrocytes (1012/L)c 4.70 ± 0.07 4.59 ± 0.07 4.54 ± 0.07 4.48 ± 0.06 0.841
Hemoglobin (g/L)c 140.4 ± 2.1 138.2 ± 1.9 137.7 ± 1.9 136.3 ± 1.9 0.635
Hematocrit (%)c 0.42 ± 0.01 0.41 ± 0.0 0.41 ± 0.01 0.40 ± 0.0 0.453
MCV (fl) 88.9 ± 0.7 89.1 ± 0.8 90.3 ± 0.8 89.5 ± 0.8 0.188
MCH (pg)c 29.9 ± 0.3 30.2 ± 0.3 30.3 ± 0.3 30.5 ± 0.3 0.914
MCHC (g/L)c 336.9 ± 1.6 338.9 ± 1.7 336.1 ± 1.5 340.5 ± 1.8 0.301
Blood thrombocytes (109/L) 255.4 ± 6.9 257.7 ± 7.7 268.0 ± 10.6 258.0 ± 9.0 0.075
ALT(𝜇kat/L) 0.46 ± 0.05 0.47 ± 0.06 0.45 ± 0.03 0.46 ± 0.04 0.800
GGT (U/L) 0.42 ± 0.05 0.41 ± 0.04 0.38 ± 0.05 0.41 ± 0.06 0.895
Creatinine (𝜇mol/L)c 70.8 ± 1.7 68.9 ± 1.9 65.6 ± 1.8d 64.2 ± 1.8 0.788
Thyroid stimulating hormone (mlE/L) 1.77 ± 0.13 1.72 ± 0.13 1.81 ± 0.17 1.93 ± 0.19 0.098
hs-CRP (mg/L) 1.54 ± 0.34 1.56 ± 0.34 1.42 ± 0.35 1.54 ± 0.40 0.838
Plasma glucose (mmol/L)c 5.04 ± 0.09 4.83 ± 0.08 5.07 ± 0.10 4.95 ± 0.12 0.573
Serum total cholesterol (mmol/L)f 6.54 ± 0.16 6.64 ± 0.18 6.49 ± 0.20 6.03 ± 0.14d,e <0.001
LDL cholesterol (mmol/L)f 4.44 ± 0.16 4.54 ± 0.17 4.35 ± 0.18 3.94 ± 0.13d,e <0.001
HDL cholesterol (mmol/L)f 1.59 ± 0.08 1.59 ± 0.08 1.71 ± 0.08 1.67 ± 0.07 0.421
Serum triglycerides (mmol/L)f 1.14 ± 0.11 1.12 ± 0.10 0.95 ± 0.06 0.93 ± 0.07 0.558
Non-HDL cholesterol (mmol/L)f 4.95 ± 0.18 5.05 ± 0.19 4.78 ± 0.19 4.36 ± 0.15d,e <0.001
Ratio LDL/HDL cholesterolf 3.02 ± 0.21 3.09 ± 0.21 2.68 ± 0.17 2.50 ± 0.16d,e 0.003
Values shown are means ± SEM. ALT: alanine aminotransferase; GGT: gamma-glutamyltransferase; hs-CRP: high sensitive C-reactive protein; MCH: mean
corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; and STAEST: plant stanol ester.
aGroup by time interaction (repeated measured variance of analysis (general linear model)).
bDifference between the groups: gender (Fisher exact test) and age (univariate analysis of variance (general linear model)).
c
𝑃 < 0.05, significant change over time.
d
𝑃 < 0.05 significantly different from control.
e
𝑃 < 0.05 significantly different from baseline.
fControl (𝑛 = 29), STAEST (𝑛 = 26).
changes in the concentrations of sterol transporting lipopro-
teins, mainly LDL. The concentrations of serum cholesterol
precursors and especially their ratios to cholesterol reflect
whole-body cholesterol synthesis, and the concentrations of
plant sterols and cholestanol and especially their ratios to
cholesterol reflect cholesterol absorption [6, 7].
2.5. Statistical Analyses. All statistical analyses were per-
formed with the SPSS for Windows 19.0 statistics program
(SPSS, Chicago, IL, USA).
Normality and homogeneity of variance assumptions
were evaluated before conducting detailed statistical analyses.
Univariate analysis of variance was used to compare the base-
line values and the changes between groups. The analysis
of variance for repeated measurements (GLM) was used to
analyze the interaction of time and groups, effect of gen-
der, and changes over time in between-group comparisons
followed by post hoc comparisons with Bonferroni correc-
tions. The nutrient intakes (protein and fiber) that signif-
icantly differed between the study groups or significantly
changed within the study group were included as covariates
in the ANCOVA analyses. Variables not normally distributed
even after logarithmic transformation or nonhomogenous
in variance or non-continuous were tested with the Mann-
Whitney U-test or Fisher exact test. A P value of <0.05 was
considered statistically significant. The results are given as
means ± SEM.
3. Results
3.1. Baseline. The baseline characteristics are shown in
Table 1. The mean age of the whole study population was
54.8 ± 1.2 yrs with a range from 30 to 66 yrs., BMI 24.1 ±
0.4 kg/m2, and serum cholesterol 6.5 ± 0.1mmol/L. There
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Table 2: Nutrient intakes during the intervention.
Control group (𝑛 = 29) STAEST group (𝑛 = 27)
𝑃
a
Baseline Intervention Baseline Intervention
Energy (MJ/d) 7.4 ± 0.3 7.9 ± 0.4 7.3 ± 0.3 7.0 ± 0.3 0.267
Fat (% of energy)b 32.5 ± 1.1 34.6 ± 1.3 34.4 ± 1.2 37.2 ± 1.6 0.668
SFA (% of energy) 12.4 ± 0.5 13.1 ± 0.6 13.0 ± 0.7 13.9 ± 0.8 0.862
MUFA (% of energy) 12.4 ± 0.5 12.9 ± 0.5 12.7 ± 0.5 14.0 ± 0.8 0.340
PUFA (% of energy) 4.8 ± 0.3 5.5 ± 0.3 5.0 ± 0.3 5.4 ± 0.3 0.741
Proteins (% of energy) 15.9 ± 0.5 16.1 ± 0.5 16.3 ± 0.5 14.9 ± 0.4c 0.029
Carbohydrates (% of energy) 42.2 ± 1.2 40.8 ± 1.0 40.6 ± 1.1 39.2 ± 1.3 0.766
Alcohol (% of energy) 3.6 ± 0.9 2.8 ± 0.6 3.2 ± 0.6 4.0 ± 0.8 0.215
Total fiber (g/d) 20.0 ± 1.1 20.6 ± 1.0 20.6 ± 1.4 17.7 ± 1.1c,d 0.032
Total fiber (g/MJ) 2.8 ± 0.2 2.7 ± 0.2 2.8 ± 0.2 2.5 ± 0.1 0.362
All values are means ± SEM. Intervention values do not contain the nutrient intake from the test minidrink. MUFA: monounsaturated fatty acids; PUFA:
polyunsaturated fatty acids; SFA: saturated fatty acids; and STAEST: plant stanol ester.
Baseline values did not differ significantly between the groups for any of the variables.
aGroup by time interaction (repeated measured variance of analysis (general linear model)).
b
𝑃 < 0.05, significant change over time.
c
𝑃 < 0.05 significantly different from baseline.
d
𝑃 < 0.05 significantly different from control.
were no significant differences in any of the clinical variables
or in the frequencies of diseases or medications (data not
shown) between the study groups, except that serum creati-
nine was lower in the STAEST group in comparison with the
controls.
3.2. Intervention
3.2.1. Weight and BMI. Weight and BMI did not change
significantly during the intervention (Table 1).
3.2.2. Feasibility of the Diet. The compliance with the con-
sumption of the test minidrinks was good. The minidrinks
were consumed on average by 97% of the intended amount,
resulting in an estimatedmean daily intake of plant stanols of
2.7 g. The intake of protein and fiber from the diet decreased
in the STAEST group with the latter differing significantly
from the controls (Table 2). The intake of fat increased
similarly from baseline in both study groups (𝑃 < 0.05), but
there were no significant changes in intakes of other nutrients
in either of the study group during the intervention. Two
subjects in each group reported gastrointestinal discomfort.
3.2.3. Safety Clinical Chemistry. The values of hemoglobin
and hematocrit, number of erythrocytes and the counts
of blood leucocytes similarly and significantly decreased,
and mean corpuscular hemoglobin and mean corpuscular
hemoglobin concentrations increased in both study groups
during the intervention, but all values remained within the
reference values (Table 1). Amino alanine aminotransferase,
gamma-glutamyltransferase, and thyroid stimulating hor-
mone levels did not change during the intervention. Serum
creatinine similarly decreased from baseline in both groups
when the baseline value was taken into account in the
statistical analysis. However, the decrease was not statistically
significant after adjustment for the changes in the nutrient
intakes.
The plasma glucose level similarly decreased from base-
line in both groups (𝑃 < 0.01). The serum high-sensitive C-
reactive protein concentration remained unchanged during
the intervention.
3.2.4. Serum Lipids. In the STAEST group, the analysis of
serum lipids could be performed from 26 subjects. Serum
total, LDL, and non-HDL cholesterol concentrations and
LDL/HDL ratio were reduced by 6.4, 8.5, 8.2, and 6.4%
compared with the baseline values in the STAEST group (𝑃 <
0.05 for all, Table 1, Figure 1). The respective reductions were
8.0, 11.1, 10.2, and 9.0% compared with controls (𝑃 < 0.05
for all). After adjustment for changes in protein and fiber
intakes, the intervention value of LDL and non-HDL choles-
terol remained statistically significantly different between
the groups (𝑃 < 0.05), but total cholesterol only tended
to differ between the groups (𝑃 = 0.072). The differences in
the percentage changes in serum total, LDL, and non-HDL
cholesterol concentrations and LDL/HDL ratio remained
significant after the adjustment for the changes in protein
andfiber intakes.TheHDLcholesterol and serum triglyceride
concentrations remained unchanged during the intervention.
3.2.5. Cholesterol Precursors, Plant Sterols, and Cholestanol.
There were no significant changes in serum squalene, choles-
tenol, or lathosterol (Figure 1) concentrations or their ratios
to cholesterol during the study (Table 3). The ratio of
serum desmosterol to cholesterol, but not its concentration,
increased similarly in both groups (𝑃 < 0.05).
Serum campesterol (Figure 1), sitosterol, and avenasterol
concentrations and their ratios to cholesterol were signifi-
cantly reduced by 12–25% and 7–20%, respectively, in the
STAEST group during the study (Table 3). The serum camp-
esterol to cholesterol ratio increased by 10% in the controls
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Table 3: Serum squalene and noncholesterol sterols during the intervention.
Control group (𝑛 = 29) STAEST group (𝑛 = 27)
𝑃
a
Baseline Intervention Baseline Intervention
Squalene (𝜇g/dL) 41.0 ± 2.4 42.8 ± 3.8 43.7 ± 2.8 40.4 ± 3.2 0.412
Cholestenol (𝜇g/dL) 45.8 ± 3.6 45.9 ± 3.0 43.9 ± 3.2 43.7 ± 2.6 0.686
Desmosterol (𝜇g/dL) 178.0 ± 6.7 183.8 ± 8.6 177.7 ± 6.4 176.2 ± 6.8 0.411
Lathosterol (𝜇g/dL) 258.6 ± 22.8 261.7 ± 21.3 262.9 ± 22.9 260.0 ± 21.5 0.660
Cholestanol (𝜇g/dL)b 371.8 ± 19.5 370.3 ± 22.5 357.6 ± 25.5 312.9 ± 14.9 0.081
Campesterol (𝜇g/dL) 650.8 ± 51.1 713.4 ± 59.1 588.7 ± 91.2 417.5 ± 54.9c,d <0.001
Sitosterol (𝜇g/dL) 371.4 ± 30.6 393.2 ± 35.8 338.4 ± 39.8 249.0 ± 23.1c,d <0.001
Sitostanol (𝜇g/dL) 31.9 ± 0.8 31.8 ± 0.9 30.5 ± 1.1 41.9 ± 1.7c,d <0.001
Avenasterol (𝜇g/dL) 101.1 ± 6.4 104.6 ± 7.5 94.7 ± 9.3 76.5 ± 5.0c,d 0.011
Ratios to cholesterol (102 mmol/mol of cholesterol)
Squalene 17.6 ± 1.1 17.8 ± 1.2 19.4 ± 1.3 19.0 ± 1.3 0.821
Cholestenol 19.9 ± 1.7 19.9 ± 1.5 19.7 ± 1.4 20.8 ± 1.2 0.379
Desmosterolb 76.0 ± 2.4 77.6 ± 2.5 79.3 ± 3.2 83.4 ± 2.9 0.198
Lathosterol 111.9 ± 9.8 112.2 ± 8.7 118.0 ± 10.3 123.1 ± 9.6 0.506
Cholestanolb 158.4 ± 7.4 155.7 ± 7.4 153.7 ± 6.2 146.7 ± 5.1 0.379
Campesterol 276.0 ± 18.7 299.1 ± 20.7c 244.3 ± 27.7 193.3 ± 22.5c,d <0.001
Sitosterol 157.6 ± 11.4 164.3 ± 12.5 142.5 ± 11.6 116.3 ± 9.6c,d <0.001
Sitostanol 13.7 ± 0.3 13.6 ± 0.3 13.4 ± 0.2 19.7 ± 0.6c,d <0.001
Avenasterol 42.9 ± 2.3 43.7 ± 2.4 40.2 ± 2.7 35.9 ± 2c,d 0.029
Values shown are means ± SEM. STAEST: plant stanol ester.
aGroup by time interaction (repeated measured variance of analysis (general linear model)).
b
𝑃 < 0.05, significant change over time.
c
𝑃 < 0.05 significantly different from baseline.
d
𝑃 < 0.05 significantly different from control.
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Figure 1: The percentage changes in LDL cholesterol (LDL-C) and
non-HDL cholesterol (non-HDL-C) concentrations and the ratios
of serum lathosterol and campesterol to cholesterol from baseline in
the control (𝑛 = 29) and STAEST groups (𝑛 = 27 except 𝑛 = 26
for LDL-C and non-HDL-C). a𝑃 < 0.05 significantly different from
control group.
(Figure 1), but no other significant changes were observed
in plant sterol concentrations or in their ratios to cholesterol
(Table 3). The differences in the changes in serum campes-
terol, sitosterol, and avenasterol concentrations and their
ratios to cholesterol were from −28 to −38% and from −21
to −47%, respectively, in the STAEST group in comparisons
with controls (𝑃 < 0.05). Adjustments taking into account the
changes in protein and fiber intakes did not alter these results.
Serum cholestanol concentrations and ratios to cholesterol
were similarly decreased by 0.4–9% and 1–4% in both study
groups (𝑃 < 0.05). After adjustment with the changes in
the nutrient intakes, the serum cholestanol concentration
declined significantly only in the STAEST group.
In the STAEST group, the serum sitostanol concentration
and the ratio to cholesterol were increased by 38% and 47%
compared with the baseline values and compared with con-
trols, but its concentration during the intervention remained
low, below 45 𝜇g/dL (Table 3).
4. Discussion
The novel finding was that consumption of 2.7 g/d of plant
stanols as stanol ester in soy-basedminidrink once a day low-
ered the LDL cholesterol level by 0.51mmol/L corresponding
to 11.1% reduction compared with controls in subjects con-
suming a habitual Western diet. In addition, serum total
and non-HDL cholesterol concentrations and the LDL/HDL
ratio were significantly reduced, and the product was well-
tolerated. There is only one previous study investigating the
addition of STAEST (2 g/d of plant stanols) to a low-fat
nondairy minidrink, that is, soymilk-based minidrink in a
Thai population where it achieved a 9% LDL cholesterol
reduction [8]. With regard to low-fat dairy products, there
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is one earlier study examining a low-fat dairy minidrink
containing STAEST (2 g/d of plant stanols) [9] and four
studies with a similar low-fat dairy minidrink but with plant
sterol ester (1.6–3 g/d of plant sterols) [10–13]. The LDL
cholesterol lowering efficacy in these studies was 8–10%. It
was also apparent that the frequency of the ingestion of low-
fat dairy or nondairyminidrinks did not affect the results; the
LDL cholesterol lowering efficacy was the same whether the
minidrink was consumed once a day [8–10, 12, 13] or twice
a day [11] either with the meal or just after the meal. The
LDL cholesterol reduction was also of the same magnitude
as encountered in the previous STAEST and plant sterol ester
studies with fat-based spreads, salad dressings or mayon-
naises, or dairy products consumed two to three times a day
with the meal [3].
The randomization of the subjects was successful, and
there were no significant differences in the background
variables at baseline, except that serum creatinine was lower
in the STAEST group as compared with the controls. The
changes in blood count and serum creatinine and plasma
glucose concentrations were similar in both groups during
the intervention, and the values remained within the refer-
ence values. The intake of protein and fiber decreased in the
STAEST group, and the intake of fiber differed significantly
from the controls. When the changes in the intake of protein
andfiberwere taken into account in the analyses as covariates,
they did not alter the results except that the intergroup
difference in the intervention value of serum total cholesterol
did not quite achieve statistical significance.
The timing of the consumption of plant stanol and sterol-
containing products has been postulated to play a crucial
role in the cholesterol-lowering efficacy. In a previous study,
when the participants consumed the plant sterol drink with
a meal, a significantly greater reduction in LDL cholesterol
was reported as compared to drinking it before breakfast or
on an empty stomach [10]. In the latter case, the minidrink
appeared to be rapidly emptied from the stomach without
triggering any contraction of the gallbladder, and thus bile
acids and biliary cholesterol were not sufficiently released into
the small intestine [14]. The lack of bile acids could interfere
with the proper formation of micelles, which are formed
through the plant stanol-cholesterol interaction. It has been
documented that plant stanols interfere with the micellar
solubility of cholesterol [15]; that is, less cholesterol is taken
up by the intestinal NPC1L1 receptor. Similar results have
been demonstrated with plant sterols such that ultimately the
amount of meal-derived cholesterol becomes reduced first in
chylomicrons and subsequently in plasma [16].
It is known that serum cholesterol precursors reflect the
whole-body cholesterol synthesis, and serum plant sterols
and cholestanol reflect the cholesterol absorption efficiency in
different populations under steady state conditions [6, 7, 17]
and during STAEST consumption [18, 19]. In general, choles-
terol absorption and synthesis are counterbalanced such that,
when cholesterol absorption is reduced, then the cholesterol
synthesis is upregulated. However, the magnitude of the
upregulation of cholesterol synthesis evoked by the plant
sterol/stanol-induced cholesterol malabsorption seems to
vary. In most of the STAEST studies, in which spread (e.g.,
[18–21]) or low-fat yoghurt [22] was consumed two to three
times a day with a meal, cholesterol synthesis was increased
[18–22]. However, in the present investigation when STAEST
in soy-based minidrink was consumed once a day with a
meal, no significant changes were found in serum cholesterol
precursor concentrations or in their ratios to cholesterol.
Similar results were obtained in subjects with type 1 diabetes
without or with statin treatment during trials with STAEST
spread [23, 24] and plant sterol ester added to mini-yoghurt
drink [11–13] or soymilk [25] consumed once [12, 13] or twice
[11] or three times [25] a day with a meal. The results with
plant sterol ester in drinkable products are not, however,
totally consistent. In one study, the addition of plant sterol
ester to semiskimmed vegetable fat-enriched milk signifi-
cantly increased the serum lathosterol to cholesterol ratio
when the milk was consumed twice a day with a meal [26].
With respect to the frequency of plant sterol consumption,
the cholesterol fractional synthesis rate tended to be greater
when plant sterol-containing spread was consumed three
times versus once a day [27]. Timing of administration has
also been examined; in one study cholesterol fractional syn-
thesis significantly increased when plant sterol-containing
low-fat yoghurt was consumedwith ameal [28]. Accordingly,
whether or not cholesterol synthesis is upregulated does not
seem to depend on the food format (solid/liquid/fat content)
or frequency of timing, and the ultimate reason remains
open.
In line with the STAEST studies with spread (e.g., [21, 29])
or low-fat yoghurt [22], in the present intervention STAEST
minidrink significantly decreased serum plant sterol con-
centrations and their ratios to cholesterol; for example, the
control-related serum campesterol to cholesterol ratio was
decreased by 30%. The reduction in serum plant sterols dur-
ing STAEST consumption reflects compliance. In previous
studies from our group where the plant stanol dose was 2.4–
3 g/d resembling the present dose, the relative serum campes-
terol reduction has varied from 35% to 43% [18, 19, 21, 29].
In the present study, in the controls the serum campesterol
to cholesterol ratio increased by 10% from baseline. This is
probably due to greater intake of vegetable oil during the
intervention period compared to the baseline even though
no significant increase in the intakes of the monounsaturated
or polyunsaturated fatty acids was detected. The serum
sitostanol concentration was increased by 11.5𝜇g/dL corre-
sponding to a relative increase of 38%. In our earlier studies,
the mean relative increase in serum sitostanol concentration
has varied from 67 to 96% with a similar plant stanol dose.
Accordingly, in the present study, the reduction in serum
plant sterols and the increase in serum sitostanol were evi-
dence of acceptable compliance.
Cholestanol is a 5𝛼-saturated derivative of cholesterol
produced by the liver. It has been shown earlier in trials where
subjects were given plant stanols that serum cholestanol
concentration and its ratio to cholesterol correlated with
the fractional cholesterol absorption [18, 19]. In the present
study, after the adjustment for the changes in protein and
fiber intakes, the serum cholestanol concentration was sig-
nificantly reduced only in the STAEST group. In some earlier
studies, the results of cholestanol concentration and its ratio
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to cholesterol have varied for unknown reasons (e.g., [23,
29]).
In conclusion, the intake of 2.7 g/day of plant stanols as an
ester once a day in a low-fat soy-based minidrink effectively
reduced serum LDL cholesterol concentrations by 11.1% in
comparison to controls consuming a regular Western diet.
Furthermore, the products did not cause any major side
effects.
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